Ian C. Gilchrist

Ian C. Gilchrist

Auto-generated profile, based on publicly available information

Ian C. Gilchrist

Geisel School of Medicine at Dartmouth, Section of Cardiovascular Medicine, Heart and Vascular Center, Dartmouth Hitchcock Medical Center, Hanover, NH (I.C.G.).

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2013 in Circulation
Verified
Journal Article
Closed access
DFDmitriy N. Feldman
Dmitriy N. Feldman
RSRajesh V. Swaminathan
Rajesh V. Swaminathan
LKLisa A. Kaltenbach
Lisa A. Kaltenbach
DBDmitri V. Baklanov
Dmitri V. Baklanov
LKLuke K. Kim
Luke K. Kim
SRSunil V. Rao
Sunil V. Rao
Background—: Radial access for percutaneous coronary intervention (r-PCI) is associated with reduced vascular complications; however, previous reports have shown that <2% of percutaneous coronary intervention (PCI) procedures in the United States are performed via the radial approach. Our aims were to evaluate temporal trends in r-PCI and compare procedural outcomes between r-PCI and transfemoral PCI. Methods and Results—: We conducted a retrospective cohort study from the CathPCI registry (n=2 820 874 procedures from 1381 sites) between January 2007 and September 2012. Multivariable logistic regression models were used to evaluate the adjusted association between r-PCI and bleeding, vascular complications, and procedural success, using transfemoral PCI as the reference. Outcomes in high-risk subgroups such as age ≥75 years, women, and patients with acute coronary syndrome were also examined. The proportion of r-PCI procedures increased from 1.2% in quarter 1 2007 to 16.1% in quarter 3 2012 and accounted for 6.3% of total procedures from 2007 to 2012 (n=178 643). After multivariable adjustment, r-PCI use in the studied cohort of patients was associated with lower risk of bleeding (adjusted odds ratio, 0.51; 95% confidence interval, 0.49–0.54) and lower risk of vascular complications (adjusted odds ratio, 0.39; 95% confidence interval, 0.31–0.50) in comparison with transfemoral PCI. The reduction in bleeding and vascular complications was consistent across important subgroups of age, sex, and clinical presentation. Conclusions—: There has been increasing adoption of r-PCI in the United States. Transradial PCI now accounts for 1 of 6 PCIs performed in contemporary clinical practice. In comparison with traditional femoral access, transradial PCI is associated with lower vascular and bleeding complication rates.

1 May 2010 in JACC
Verified
Journal Article
Closed access
SRSunil V. Rao
Sunil V. Rao
MCMauricio G. Cohen
Mauricio G. Cohen
DKDavid E. Kandzari
David E. Kandzari
OBOlivier F. Bertrand
Olivier F. Bertrand
IGIan C. Gilchrist
Ian C. Gilchrist

3 October 2023 in Circulation
Verified
Journal Article
Closed access
RWRon Waksman
Ron Waksman
MPMohit Pahuja
Mohit Pahuja
SDSean van Diepen
Sean van Diepen
APAlastair G. Proudfoot
Alastair G. Proudfoot
DMDavid Morrow
David Morrow
WAWilliam T. Abraham
William T. Abraham
The Shock Academic Research Consortium is a multi-stakeholder group, including representatives from the US Food and Drug Administration and other government agencies, industry, and payers, convened to develop pragmatic consensus definitions useful for the evaluation of clinical trials enrolling patients with cardiogenic shock, including trials evaluating mechanical circulatory support devices. Several in-person and virtual meetings were convened between 2020 and 2022 to discuss the need for developing the standardized definitions required for evaluation of mechanical circulatory support devices in clinical trials for cardiogenic shock patients. The expert panel identified key concepts and topics by performing literature reviews, including previous clinical trials, while recognizing current challenges and the need to advance evidence-based practice and statistical analysis to support future clinical trials. For each category, a lead (primary) author was assigned to perform a literature search and draft a proposed definition, which was presented to the subgroup. These definitions were further modified after feedback from the expert panel meetings until a consensus was reached. This manuscript summarizes the expert panel recommendations focused on outcome definitions, including efficacy and safety.

4 May 2011 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
RCRonald P. Caputo
Ronald P. Caputo
JTJennifer A. Tremmel
Jennifer A. Tremmel
SRSunil Rao
Sunil Rao
IGIan C. Gilchrist
Ian C. Gilchrist
CPChristopher Pyne
Christopher Pyne
TPTejas Patel
Tejas Patel

1 March 2006 in American Heart Journal
Verified
Journal Article
Closed access
AGAdam B. Greenbaum
Adam B. Greenbaum
CGCindy L. Grines
Cindy L. Grines
JBJohn A. Bittl
John A. Bittl
RBRichard C. Becker
Richard C. Becker
DKDean J. Kereiakes
Dean J. Kereiakes
WWW. Douglas Weaver
W. Douglas Weaver

3 June 2008 in Circulation
Verified
Journal Article
Closed access
PDF file
MCMark Y Chan
Mark Y Chan
MCMauricio G. Cohen
Mauricio G. Cohen
CDChristopher K. Dyke
Christopher K. Dyke
SMShelley K. Myles
Shelley K. Myles
LALaura G. Aberle
Laura G. Aberle
CRChristopher P. Rusconi
Christopher P. Rusconi
Background—Whether selective factor IXa inhibition produces an appropriate anticoagulant effect when combined with platelet-directed therapy in patients with stable coronary artery disease is unknown. REG1 consists of RB006 (drug), an injectable RNA aptamer that specifically binds and inhibits factor IXa, and RB007 (antidote), the complementary oligonucleotide that neutralizes its anti-IXa activity.Methods and Results—We evaluated the safety, tolerability, and pharmacodynamic profile of REG1 in a randomized, double-blind, placebo-controlled study, assigning 50 subjects with coronary artery disease taking aspirin and/or clopidogrel to 4 dose levels of RB006 (15, 30, 50, and 75 mg) and RB007 (30, 60, 100, and 150 mg). The median age was 61 years (25th and 75th percentiles, 56 and 68 years), and 80% of patients were male. RB006 increased the activated partial thromboplastin time dose dependently; the median activated partial thromboplastin time at 10 minutes after a single intravenous bolus of 15, 30, 50, and 75 mg RB006 was 29.2 seconds (25th and 75th percentiles, 28.1 and 29.8 seconds), 34.6 seconds (25th and 75th percentiles, 30.9 and 40.0 seconds), 46.9 seconds (25th and 75th percentiles, 40.3 and 51.1 seconds), and 52.2 seconds (25th and 75th percentiles, 46.3 and 58.6) (P<0.0001; normal 25th and 75th percentiles, 27 and 40 seconds). RB007 reversed the activated partial thromboplastin time to baseline levels within a median of 1 minute (25th and 75th percentiles, 1 and 2 minutes) with no rebound increase through 7 days. No major bleeding or other serious adverse events occurred.Conclusions—This is the first experience of an RNA aptamer drug-antidote pair achieving inhibition and active restoration of factor IXa activity in combination with platelet-directed therapy in stable coronary artery disease. The preliminary clinical safety and predictable pharmacodynamic effects form the basis for ongoing studies in patients undergoing elective revascularization procedures.